The PEPperCHIP® Cancer Neoepitope Microarrays is a customized peptide microarray covering up to 5,500 peptides in duplicates for the personalized analysis of anti-tumor antibody responses. The microarray can be designed using up to 2,750 wild type vs. mutant peptide pairs or using a combination of genomic sequencing derived protein and /or tumor-associated antigens as highly overlapping peptides. The degree of peptide-peptide overlap (e.g. shift 1 to 3) can be selected. Moreover, the microarray contains HA, polio and c-Myc positive control peptides.
Each tumor exhibits an individual cancer mutation profile with shared and patient unique mutations. The resulting neoantigens can elicit strong immune responses with detectable antibody levels in patient sera.
The fingerprint analysis of antibody profiles to neoepitopes could precisely distinguish between immunogenic and non-immunogenic mutations, a prerequisite for high-precision cancer immunotherapy and cancer vaccine development. Antibody responses to neoepitopes could be compared in treatment responders and non-responders to search for predictive biomarkers.
Furthermore, neoepitope response profiles could be a source to predict side effects to therapy.
The PEPperCHIP® Cancer Neoepitope Microarray can be used for the following applications
• | Validate therapeutic antibodies against tumor associated antigens |
• | Target Discovery: Identify immunogenic epitopes for immunotherapy |
• | Develop personalized cancer vaccines |
• | Monitor patient-specific anti-tumor antibody responses |
• | Discover prognostic cancer neoepitopes |
What our customers say
"We have rigorously tested the reproducibility, sensitivity, and specificity of peptide microarrays provided by the PEPperPRINT using biological samples and have published two papers. […] We found this platform to be extremely useful for our studies. These dedicated efforts are testament to the standard of excellence maintained by PEPperPRINT’s scientific staff, for continued improvement and innovation of peptide microarray technology."
Prof. David Han, UConn Health
Microarray information
• | Microarray content: Custom cancer neoepitope microarray corresponding to 2750 wild type/mutant peptide pairs |
• | Peptide length and overlap: 3 aa to 15 aa depending on the epitope length |
• | Number of peptides / spots: 5,500 / 11,000 (peptides printed in duplicate) |
• | Positive control: HA (YPYDVPDYAG), polio (KEVPALTAVETGAT) and c-Myc (EQKLISEEDL) control peptides |
• | Size and format: 3'' x 1'', 75.4 mm x 25.0 mm x 1.0 mm, containing 1 array copy per chip |
• | Accessories: compatible with 3/1 well PEPperCHIP® Incubation Tray |
Sample information
• | Can be assayed with at least 20 µL serum/plasma or 10-20 µg/mL purified antibody. |
Estimated delivery time
• | 1-4 weeks for chip and optional add-on accessories |
• | 6-8 weeks when requested with PEPperMAP® Services. |
Documentation
• | PEPperCHIP® Cancer Neoepitope Microarray product flyer [download pdf] |
Learn how to perform the assay
• | PEPperCHIP® Immunoassay Protocol [download pdf] [watch video] |
• | PEPperCHIP® Immunoassay Quickstart Guide [download pdf] |
Steps | Materials and equipment | We recommend |
Immunoassay | Incubation tray | PEPperCHIP® Incubation Tray* |
Orbital shaker | - | |
Blocking reagents | BSA, or Rockland Blocking Buffer* | |
Control antibodies | PEPperCHIP® Control Antibodies | |
Buffers | PBS, Tween 20 | |
Labelled secondary antibodies | Rockland secondary antibodies* | |
Data acquisition | Microarray scanner | Innopsys InnoScan® 710/710-IR* |
Data analysis | Fluorescence spot intensity quantification software | MAPIX Analyzer by Innopsys |
Spreadsheet software | - |
*used in-house by PEPperPRINT
Discovery of Putative Breast Cancer Antigens Using an Integrative Platform of Genomics-Driven Immunoproteomics.
Veneta Qendro, Deborah H. Lundgren, Samuel Palczewski, Poornima Hegde, Christina Stevenson, Laurie Perpetua, Ardian Latifi, Jesse Merriman, Grace Bugos, and David K. Han. PROTEOMICS 17, no. 15–16 (August 2017): 1600318. [doi.org/10.1002/pmic.201600318]
Integrative Proteomics, Genomics, and Translational Immunology Approaches Reveal Mutated Forms of Proteolipid Protein 1 (PLP1) and Mutant-Specific Immune Response in Multiple Sclerosis.
Veneta Qendro, Grace A. Bugos, Debbie H. Lundgren, John Glynn, May H. Han, and David K. Han. PROTEOMICS 17, no. 6 (March 2017): 1600322. [doi.org/10.1002/pmic.201600322]
Genomics-Driven Immunoproteomics: An Integrative Platform to Uncover Important Biomarkers for Human Diseases.
Raghavendra Giri, Veneta Qendro, Pooja Rani, Carren Jepchumba, Grace Bugos, Volker Stadler, and David K. Han. In Immunoproteomics, edited by Kelly M. Fulton and Susan M. Twine, 2024:327–32. New York, NY: Springer New York, 2019. [doi.org/10.1007/978-1-4939-9597-4_21]
<s>For off-the-shelf products, see Standard chips and accessories checklist.xlsx for the product description that goes in this section.</s>
<s>475.00 EUR</s>
Excl. tax and shipping costs.
